MX2024005342A - Análogos de auristatina novedosos e inmunoconjugados de estos. - Google Patents

Análogos de auristatina novedosos e inmunoconjugados de estos.

Info

Publication number
MX2024005342A
MX2024005342A MX2024005342A MX2024005342A MX2024005342A MX 2024005342 A MX2024005342 A MX 2024005342A MX 2024005342 A MX2024005342 A MX 2024005342A MX 2024005342 A MX2024005342 A MX 2024005342A MX 2024005342 A MX2024005342 A MX 2024005342A
Authority
MX
Mexico
Prior art keywords
immunoconjugates
auristatin analogs
novel auristatin
novel
analogs
Prior art date
Application number
MX2024005342A
Other languages
English (en)
Spanish (es)
Inventor
Richard Hui Li
Dong Jun Lee
Original Assignee
Adcentrx Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adcentrx Therapeutics Inc filed Critical Adcentrx Therapeutics Inc
Publication of MX2024005342A publication Critical patent/MX2024005342A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
MX2024005342A 2021-11-03 2022-11-02 Análogos de auristatina novedosos e inmunoconjugados de estos. MX2024005342A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163275177P 2021-11-03 2021-11-03
US202163295476P 2021-12-30 2021-12-30
PCT/US2022/048735 WO2023081230A1 (en) 2021-11-03 2022-11-02 Novel auristatin analogs and immunoconjugates thereof

Publications (1)

Publication Number Publication Date
MX2024005342A true MX2024005342A (es) 2024-09-27

Family

ID=86241915

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024005342A MX2024005342A (es) 2021-11-03 2022-11-02 Análogos de auristatina novedosos e inmunoconjugados de estos.

Country Status (10)

Country Link
US (1) US20260131016A1 (enExample)
EP (1) EP4426714A4 (enExample)
JP (1) JP2024540402A (enExample)
KR (1) KR20240110584A (enExample)
AU (1) AU2022380491A1 (enExample)
CA (1) CA3236944A1 (enExample)
IL (1) IL312533A (enExample)
MX (1) MX2024005342A (enExample)
TW (1) TW202334176A (enExample)
WO (1) WO2023081230A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4786483A1 (en) 2023-09-26 2026-08-05 Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. Auristatin derivative and antibody-drug conjugate thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2605443T3 (es) * 2003-11-06 2017-03-14 Seattle Genetics, Inc. Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia
US20130190248A1 (en) * 2011-07-26 2013-07-25 Agensys, Inc. Substituted peptide analogs
US20130280282A1 (en) * 2012-04-24 2013-10-24 Daiichi Sankyo Co., Ltd. Dr5 ligand drug conjugates
AR097161A1 (es) * 2013-08-01 2016-02-24 Agensys Inc Conjugados de fármacos anticuerpo (adc) que se unen a las proteínas cd37
PL3204425T3 (pl) * 2014-10-09 2021-03-08 Genzyme Corporation Glikomodyfikowane koniugaty przeciwciał z lekami
US20170014524A1 (en) * 2015-07-15 2017-01-19 The California Institute For Biomedical Research Auristatin-antibody conjugates and uses thereof

Also Published As

Publication number Publication date
KR20240110584A (ko) 2024-07-15
EP4426714A1 (en) 2024-09-11
TW202334176A (zh) 2023-09-01
AU2022380491A1 (en) 2024-05-30
WO2023081230A1 (en) 2023-05-11
CA3236944A1 (en) 2023-05-11
EP4426714A4 (en) 2025-10-08
US20260131016A1 (en) 2026-05-14
JP2024540402A (ja) 2024-10-31
IL312533A (en) 2024-07-01

Similar Documents

Publication Publication Date Title
ECSP22098041A (es) Inhibidores alostéricos de egfr y métodos de uso de estos
MX2022006700A (es) Compuestos poliheterociclicos como inhibidores de mettl3.
UA130338C2 (uk) Кон'югат ліганд-лікарський засіб аналога ексатекану, спосіб його отримання та його застосування
MX2022002740A (es) Conjugados de il-2 y metodos de uso para tratar enfermedades autoinmunes.
ECSP034428A (es) Ciclopentanoindoles, composiciones conteniendo tales compuestos y su uso
PE20221417A1 (es) Degradadores bifuncionales de brd9 y sus metodos de uso
CL2021002503A1 (es) Anticuerpos contra triptasa, composiciones de estos y usos de estos. (divisional de solicitud 201902251)
CL2019002255A1 (es) 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas.
MX2022009596A (es) Anticuerpos anti-ror1 y composiciones.
PE20200494A1 (es) Polinucleotidos de aadc para el tratamiento de la enfermedad de parkinson
ECSP21026485A (es) Piridazinonas y sus métodos de uso
AR123685A1 (es) Antagonistas del mrgx2
PA8583101A1 (es) Nuevos compuestos de isotiazol e isoxazol como inhibidores del factor de crecimiento transformador (tgf)
JOP20210164A1 (ar) طرق وتركيبات علاج السرطان
MX2023009874A (es) Anticuerpos anti-psma y estructuras car-t.
MX389724B (es) Compuestos de fenil-2-hidroxi-acetilamino-2-metil-fenilo
CO2018011819A2 (es) Inhibidores del potenciador del homólogo zeste 2
CL2025002873A1 (es) Anticuerpos anti-cd19 y estructuras car-t
CR10062A (es) Composiciones y metodos de tratamiento para trastornos del sistema nervioso central
MX2024008450A (es) Piperidinil-metil-purina aminas enriquecidas con deuterio y compuestos relacionados y su uso en el tratamiento de enfermedades y condiciones
CO2022006466A2 (es) Inhibidores de egfr alostéricos y métodos de uso de los mismos
DOP2025000220A (es) Compuestos bifuncionales capaces de degradar receptores de andrógenos
MX2020012281A (es) Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiacepinona y metodos de uso de las mismas.
CO2025002334A2 (es) Derivados arilos tricíclicos, y composiciones y métodos de los mismos
PA8567701A1 (es) Agonistas del receptor b3-adrenergico